Growth & profitability
- Revenue has grown 46.8% per year over the past 5 years.
- Operating margin has expanded, at -95.2% in the latest year.
XBIO Financials Xenetic Biosciences, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | -$3M | 0.0% | -95.2% | — | — | $8M |
| 2024 | $3M | -$4M | 0.0% | -168.2% | — | — | $6M |
| 2023 | $3M | -$4M | 0.0% | -177.8% | — | — | $9M |
| 2022 | $2M | -$7M | 0.0% | -393.6% | — | — | $13M |
| 2021 | $1M | -$6M | 0.0% | -495.1% | — | — | $18M |
| 2020 | $436942 | -$11M | 0.0% | -3189.8% | — | — | $12M |
| 2019 | $17066 | -$13M | 0.0% | -75511.7% | — | — | $10M |
| 2018 | $0 | -$7M | — | — | -$6M | — | $638115 |
| 2017 | $8M | -$4M | 0.0% | -47.1% | $1M | — | $6M |
| 2016 | $3M | -$54M | 0.0% | -1581.0% | -$9M | — | $4M |
| 2015 | $0 | -$13M | — | — | — | — | — |
| 2014 | $0 | -$14M | — | — | — | — | — |
| 2013 | $1M | -$9M | 100.0% | -861.3% | -$6M | — | — |
| 2013 | $96900 | -$89172 | 0.0% | -67.7% | $68109 | $425626 | — |
| 2013 | $217725 | -$150990 | 95.4% | -58.5% | — | $425626 | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $806923 | -$456382 | 0.0% | -62.2% | — | — | $7M |
| Dec '25 | $766296 | -$579076 | 0.0% | -81.3% | — | — | $8M |
| Sep '25 | $1M | -$509940 | 0.0% | -53.0% | — | — | $4M |
| Jun '25 | $589897 | -$688703 | 0.0% | -122.8% | — | — | $5M |
| Mar '25 | $593261 | -$903141 | 0.0% | -158.9% | — | — | $5M |
| Dec '24 | $648820 | -$1M | 0.0% | -169.4% | — | — | $6M |
| Sep '24 | $614243 | -$436671 | 0.0% | -81.3% | — | — | $7M |
| Jun '24 | $726404 | -$1M | 0.0% | -184.1% | — | — | $7M |
| Mar '24 | $510817 | -$1M | 0.0% | -248.3% | — | — | $8M |
| Dec '23 | $671963 | -$1M | 0.0% | -186.9% | — | — | $9M |
| Sep '23 | $611174 | -$1M | 0.0% | -187.6% | — | — | $10M |
| Jun '23 | $651005 | -$1M | 0.0% | -184.1% | — | — | $11M |
| Mar '23 | $605844 | -$856554 | 0.0% | -151.1% | — | — | $12M |
| Dec '22 | $486972 | -$1M | 0.0% | -321.0% | — | — | $13M |
| Sep '22 | $414250 | -$804017 | 0.0% | -204.7% | — | — | $14M |
| Jun '22 | $416710 | -$3M | 0.0% | -644.8% | — | — | $15M |
| Mar '22 | $388993 | -$2M | 0.0% | -416.4% | — | — | $16M |
| Dec '21 | $332604 | -$2M | 0.0% | -563.4% | — | — | $18M |
| Sep '21 | $349269 | -$1M | 0.0% | -394.0% | — | — | $20M |
| Jun '21 | $287603 | -$1M | 0.0% | -392.1% | — | — | $9M |
Valuation over time
How the market has priced XBIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 0.5× (Mar '23) to 2.2× (Jun '26).
P/S
Frequently asked questions
Is XBIO growing its revenue and profit?
Over the past 5 years, Xenetic Biosciences, Inc.'s revenue has grown 46.8% per year. These are computed facts, not advice.
How much debt does XBIO have?
As of FY2025, Xenetic Biosciences, Inc. reported — of total debt against $8M of cash.
What is XBIO's profit margin?
In FY2025, gross margin was —, operating margin -95.2%, and net margin -90.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.